SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 16.62 |
| Enterprise Value ($M) | 11.23 |
| Book Value ($M) | 3.23 |
| Book Value / Share | 0.87 |
| Price / Book | 5.15 |
| NCAV ($M) | 1.03 |
| NCAV / Share | 0.28 |
| Price / NCAV | 16.20 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -3.59 |
| Return on Assets (ROA) | -0.95 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.37 |
| Current Ratio | 1.37 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 7.16 |
| Assets | 9.36 |
| Liabilities | 6.14 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -33.33 |
| Net Income | -4.79 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -24.13 |
| Cash from Investing | -0.68 |
| Cash from Financing | 4.42 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | 3i, LP | 9.90 | ||
| 13D/A | L5 Capital Inc. | 10.70 | 1.96 | |
| 13G/A | CVI Investments, Inc. | 1.90 | -77.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 87,313 | 427,694 | 20.41 | |
| 2,148,344 | 6,688,253 | 32.12 | |
| 58,249 | 187,693 | 31.03 | |
| 85,459 | 310,689 | 27.51 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| AYTU – Aytu BioPharma, Inc. | BCDA – BioCardia, Inc. |
| BCLI – Brainstorm Cell Therapeutics Inc. | BFRG – Bullfrog AI Holdings, Inc. |
| BFRI – Biofrontera Inc. |
Financial data and stock pages provided by
Fintel.io